Sumitomo Pharma America, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$12Mgeneral payments (2019-2025)
$862Kresearch payments (2019-2025)
62,174clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2023 $5.1M
2024 $3.6M
2025 $3.7M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Urology $3.7M
Obstetrics & Gynecology $1.3M
Family $776K
Family Medicine $724K
Physician Assistant $509K
Internal Medicine $498K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
William White Farmington, CT Hypertension Specialist $342,445.00
Matt Rosenberg Jackson, MI Family Medicine $210,416.88
Jeffrey Frankel Burien, WA $209,833.42
David Staskin Brighton, MA Urology $186,395.51
Edwin Parsley Houston, TX Critical Care Medicine (Internal Medicine) $166,879.15
Michael Kennelly Charlotte, NC Urology $140,174.51
Sean Collins Washington, DC Radiation Oncology $103,327.35
Ashley Tapscott Nashville, TN Urology $102,033.06
Vahan Kassabian Roswell, GA Urology $98,229.38
Nathaniel Barnes Webster, TX Urology $97,913.83

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.